L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-alzheimer's transgenic mice

Journal of Alzheimer's Disease

Volumn 29, Issue 2, 2012, Pages 379-391

  Peng, Ying ^a   Hu, Yanli ^a,b   Xu, Shaofeng ^a   Li, Pingping ^a   Li, Jiang ^a   Lu, Li ^a   Yang, Hongyan ^a   Feng, Nan ^a   Wang, Ling ^a   Wang, Xiaoliang ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b SHIHEZI UNIVERSITY   (China)

Author keywords

Alzheimer's disease; amyloid ; CDK 5; GSK 3 ; L 3 n butylphthalide; tau

Indexed keywords

3 BUTYLPHTHALIDE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA ACTIN; CYCLIN DEPENDENT KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; PRESENILIN 1; SERINE; TAU PROTEIN; THREONINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOACCUMULATION; BRAIN CORTEX; BRAIN HOMOGENATE; CELERY; COGNITIVE DEFECT; CONTROLLED STUDY; GLIA; HIPPOCAMPUS; LEARNING; MALE; MEMORY DISORDER; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PLANT SEED; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SPATIAL MEMORY; TRANSGENIC MOUSE; WILD TYPE;

EID: 84859398030     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111577     Document Type: Article

References (41)

1. Selkoe DJ (1994) Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17, 489-517. (Pubitemid 24117040)
2. Busciglio J, Lorenzo A, Yeh J, Yankner BA (1995) beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14, 879-888.
3. Park SY, Tournell C, Sinjoanu RC, Ferreira A (2007) Caspase-3-and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons. Neuroscience 144, 119-127. (Pubitemid 44841997)
4. Churcher I (2006) Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr Top Med Chem 6, 579-595.
5. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3, 1141-1154. (Pubitemid 23088964)
6. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33, 95-130.
7. Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8, 783-793.
8. Hanger DP, Anderton BH, Noble W (2009) Tau phosphoryla-tion: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119.
9. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribé E, Dalfó E, Avila J (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2, 3-18. (Pubitemid 41389255)
10. Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphos-phorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20, 27-39. (Pubitemid 32099099)
11. Pei JJ, Grundke-Iqbal I, Iqbal K, Bogdanovic N, Winblad B, Cowburn RF (1998) Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 797, 267-277. (Pubitemid 28332739)
12. Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH (2006) p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci 26, 10536-10541. (Pubitemid 44564604)
13. Phiel CJ, Wilson CA, Lee VMY, Klein PS (2003) GSK-3a regulated production of Alzheimer's disease amyloid-fj peptides. Nature 423, 435-439. (Pubitemid 36626994)
14. Medina M, Castro A (2008) Glycogen synthase kinase-3 (GSK-3) inhibitors reach to clinic. Curr Opin Drug Discov Dev 11, 533-543. (Pubitemid 351950847)
15. Le Corre S, Klafki HW, Plesnila N, Hübinger G, Obermeier A, Sahagun H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM (2006) An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl AcadSci USA 103, 9673-9678. (Pubitemid 43955883)
16. Peng Y, Xu SF, Chen GQ, Wang L, Feng YP, Wang XL (2007) L-3-n-Butylphthalide improves cognitive impairment induced by chronic cerebral hypoperfusion in rats. J Pharma col Exp Ther 321, 902-910. (Pubitemid 46762705)
17. Peng Y, Xing CH, Xu SF, Lemere CA, Chen GQ, Liu B, Wang L, Feng YP, Wang XL (2009) L-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-fj peptide in rats. Eur J Pharmacol 621, 38-45.
18. Ma SP, Xu SF, Liu B, Li J, Feng N, Wang L, Wang XL (2009) Long-term treatment of l-3-n-butylphthalide attenuated neurodegenerative changes in aged rats. Naunyn-Schmied Arch Pharmacol 379, 565-574.
19. Peng Y, Xing CH, Lemere CA, Chen GQ, Xu SF, Wang L, Feng YP, Wang XL (2008) L-3-n-butylphthalide Ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells. Neurosci Lett 434, 224-229.
20. Peng Y, Hu YL, Xu SF, Feng N, Wang L, Feng YP, Wang XL (2011) L-3-n-butylphthalide regulates amyloid precursor protein processing by PKC and MAPK pathways in SK-N-SH Cells Over-Expressing Wild Type Human APP695. Neurosci Lett 487, 211-216.
21. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O (2004) Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 55, 801-814. (Pubitemid 38702575)
22. Ding Y, Qiao A, Wang Z, Goodwin JS, Lee ES, Block ML, Allsbrook M, McDonald MP, Fan GH (2008) Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci 28, 11622-11634.
23. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple trans-genes in mouse CNS: A comparison of strategies. Biomol Eng 17, 157-165. (Pubitemid 32409891)
24. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Meth 11, 47-60. (Pubitemid 14088970)
25. Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, Wang X, Lemere CA (2010) L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. J Neurosci 30, 8180-8189.
26. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duyckaerts C, Tremp G, Pradier L (2003) Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol 184, 247-263. (Pubitemid 37444035)
27. Kurt MA, Davies DC, Kidd M, Duff K, Howlett DR (2003) Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol Dis 14, 89-97. (Pubitemid 37103183)
28. Wang JZ, Wu Q, Smith A, Grundke-Iqbal I, Iqbal K (1998) Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett 436, 28-34. (Pubitemid 28454601)
29. Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2, 769-776. (Pubitemid 33679839)
30. Sharma P, Sharma M, Amin ND, Albers RW, Pant HC (1999) Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proc Natl Acad Sci USA 96, 11156-11560.
31. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG (2000) A learning deficit related to age and beta-amyloid plaques in amouse model of Alzheimer's disease.Nature 408, 975-979. (Pubitemid 32101643)
32. Schindowski K, Bretteville A, Leroy K, Bégard S, Brion JP, Hamdane M, Buée L (2006) Alzheimer's disease-like tau neu-ropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169, 599-616. (Pubitemid 44156317)
33. Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the mammalian central nervous system. J Cell Biol 101, 1371-1378. (Pubitemid 16203754)
34. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegener-ative tauopathies. Annu Rev Neurosci 24, 1121-1159.
35. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
36. Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, Hasegawa M, Ihara Y, Miyamoto E, Miyakawa T (1996) Sequential changes of tau-site-specific phosphoryla-tion during developmentofpaired helicalfilaments.Dementia 7, 177-181. (Pubitemid 26276516)
37. Rankin CA, Sun Q, Gamblin TC (2005) Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation. Brain Res Mol Brain Res 138, 84-93. (Pubitemid 41032932)
38. Greenberg SG, Davies P, Schein JD, Binder LI (1992) Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem 267, 564-569.
39. Paudel HK, Lew J, Ali Z, Wang JH (1993) Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helicalfilaments.J Biol Chem268, 23512-23516.
40. Fath T, Eidenmüller J, Brandt R (2002) Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's diseasese. J Neurosci 22, 9733-9741. (Pubitemid 35332856)
41. Lovestone S, Reynolds CH (1997) The phosphorylation of tau: A critical stage in neurodevelopment and neurodegener-ative processes. Neuroscience 78, 309-324. (Pubitemid 27170324)